{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glargine",
    "query": {
      "intervention": "glargine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 306,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glargine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T05:30:08.068Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00353834",
      "title": "The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Glargine Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joslin Diabetes Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2006-08",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-09",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00353834"
    },
    {
      "nct_id": "NCT00309465",
      "title": "Perioperative Insulin Glargine Dosing Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes",
        "Surgery"
      ],
      "interventions": [
        {
          "name": "Lantus",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tamra Dukatz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2005-10",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-12-03",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 2,
      "location_summary": "Royal Oak, Michigan • Troy, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Troy",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309465"
    },
    {
      "nct_id": "NCT01952145",
      "title": "A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec/liraglutide",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2013-09-20",
      "completion_date": "2014-11-04",
      "has_results": true,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 31,
      "location_summary": "Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952145"
    },
    {
      "nct_id": "NCT01226043",
      "title": "Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 405,
      "start_date": "2010-10",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-12",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01226043"
    },
    {
      "nct_id": "NCT00177398",
      "title": "Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Glargine insulin vs regular insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-02",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-19",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00177398"
    },
    {
      "nct_id": "NCT07076199",
      "title": "A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Insulin icodec",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 877,
      "start_date": "2025-08-11",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 103,
      "location_summary": "Cullman, Alabama • Concord, California • Escondido, California + 85 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076199"
    },
    {
      "nct_id": "NCT00598793",
      "title": "Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "biphasic insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 242,
      "start_date": "2002-11",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 27,
      "location_summary": "Concord, California • Los Angeles, California • Walnut Creek, California + 20 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00598793"
    },
    {
      "nct_id": "NCT03260868",
      "title": "Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine, 300 units per milliliter (U/mL)",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-09-19",
      "completion_date": "2018-11-22",
      "has_results": true,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 3,
      "location_summary": "West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia",
      "locations": [
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Bridgeport",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260868"
    },
    {
      "nct_id": "NCT05013229",
      "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "IcoSema",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 679,
      "start_date": "2021-11-30",
      "completion_date": "2023-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 66,
      "location_summary": "Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013229"
    },
    {
      "nct_id": "NCT00097877",
      "title": "Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "biphasic insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 293,
      "start_date": "2005-01",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-10T05:30:08.068Z",
      "location_count": 71,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097877"
    }
  ]
}